Characteristic |
Patients (n = 84) |
---|---|
Age, mean (range; 95% CI) | 55 (18–85; 52–59) |
Gender, n (%) | |
Male | 58 (69) |
Female | 26 (31) |
Cardiovascular risk factors, n (%) | |
Arterial hypertension | 37 (44) |
Hypercholesterinemia | 21 (25) |
Cardiac family history | 15 (18) |
Smoking status | 32 (38) |
Diabetes mellitus | 11 (13) |
Adipositas | 12 (14) |
Laboratory parameters, median (IQR) | |
Creatinine (mg/dL) | 0.89 (0.78–1.04) |
GFR (mL/min) | 89 (75–101) |
Prior medical history, n (%) | |
Chronic heart failure | 26 (31) |
NYHA I | 10 (38) |
NYHA II | 14 (54) |
NYHA III | 2 (8) |
NYHA IV | 0 (0) |
Atrial fibrillation | 13 (15) |
Paroxysmal | 8 (10) |
Persistent | 3 (4) |
Permanent | 2 (2) |
Coronary artery disease | 26 (31) |
1 vessel disease | 10 (12) |
2 vessel disease | 3 (4) |
3 vessel disease | 13 (15) |
Past history of myocardial infarction | 17 (20) |
Valvular heart disease | 31 (37) |
Chronic kidney disease | 7 (8) |
COPD | 7 (8) |
Asthma | 6 (7) |
Pneumonia | 2 (2) |
Pulmonary hypertension | 1 (1) |
Cancer | 7 (8) |
Medication, n (%) | |
ACE-inhibitor/AT1-receptor antagonist | 43 (51) |
Beta blocker | 43 (51) |
Aldosterone antagonist | 15 (18) |
Calcium antagonist | 18 (21) |
Diuretics | 45 (54) |
Acetylsalicylic acid | 32 (38) |
Thienopyridines | 9 (11) |
OAC/NOAC | 14 (17) |
Statin | 34 (40) |